GSK Sets Sights On ViiV HIV Spin-Out In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Andrew Witty said the company will explore the possibility of an IPO of a minority stake in ViiV, an HIV-centric joint venture with Pfizer and Shionogi, as the company continues to reshape its business.
You may also be interested in...
ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value
The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.
GSK Plans £1 Bil. In Cuts As Respiratory Strategy Fails To Deliver
Britain’s biggest drug maker said it will cut costs by £1 billion in three years as sales of its blockbuster Advair continued to fall under increasing pricing pressure; the company also unveiled key management changes, including within its top R&D slots.
GSK Plans £1 Bil. In Cuts As Respiratory Strategy Fails To Deliver
Britain’s biggest drug maker said it will cut costs by £1 billion in three years as sales of its blockbuster Advair continued to fall under increasing pricing pressure; the company also unveiled key management changes, including within its top R&D slots.